Literature DB >> 19959119

Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF.

Mandeep R Mehra1, Clyde W Yancy, Nancy M Albert, Anne B Curtis, Wendy Gattis Stough, Mihai Gheorghiade, J Thomas Heywood, Mark L McBride, Christopher M O'Connor, Dwight Reynolds, Mary Norine Walsh, Gregg C Fonarow.   

Abstract

BACKGROUND: Clinical guidelines recommend implantable cardioverter-defibrillators (ICDs) for selected patients with chronic left ventricular dysfunction (LVD) to improve survival, yet ICD treatment rates for eligible patients with LVD or heart failure (HF) in cardiology practices remain poorly studied.
OBJECTIVE: This study sought to determine patient and practice characteristics associated with ICD use in the outpatient setting.
METHODS: IMPROVE HF (Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting), a prospective cohort study, is designed to characterize management of HF with reduced left ventricular ejection fraction (LVEF < or =35%). Baseline data were collected for 15,381 patients attending 167 outpatient cardiology practices located in the U.S.
RESULTS: By current guidelines, 7,221 patients met eligibility for ICD implantation (+/- cardiac resynchronization therapy [CRT]), of whom 3,659 (50.7%) received either ICD (63.8%) or CRT with defibrillator (36.2%). Individual practice conformity for guideline-recommended ICD use ranged from 0% to 100% (27.3% to 74.6% at the 10th and 90th percentiles, respectively). Adjusted analyses revealed lack of adherence for ICD use most notably with advancing age (odds ratio: 0.87; 95% confidence interval: 0.82 to 0.93 per 10 years), black race (odds ratio: 0.75; 95% confidence interval: 0.60 to 0.94), and lack of insurance (odds ratio: 0.45; 95% confidence interval: 0.26 to 0.78). Characteristics of increased adherence included male sex, ischemic disease, atrial fibrillation, and wider QRS. Practices in the Northeast U.S. were more likely to adhere to guidelines (P <.001), as were those with a dedicated HF clinic (P = .004) and electrophysiologists on staff (P <.001).
CONCLUSION: Although a number of patient and practice characteristics are associated with guideline-based ICD use, there is significant unexplained variation in the use of ICD therapy for sudden death prophylaxis across cardiology practices.

Entities:  

Mesh:

Year:  2009        PMID: 19959119     DOI: 10.1016/j.hrthm.2009.08.022

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  9 in total

1.  Referring physicians' discordance with the primary prevention implantable cardioverter-defibrillator guidelines: a national survey.

Authors:  Jorge M Castellanos; Lisa M Smith; Paul D Varosy; Christine Dehlendorf; Gregory M Marcus
Journal:  Heart Rhythm       Date:  2012-02-02       Impact factor: 6.343

Review 2.  Indications for implantable cardioverter-defibrillator placement in ischemic cardiomyopathy and after myocardial infarction.

Authors:  Stavros E Mountantonakis; Mathew D Hutchinson
Journal:  Curr Heart Fail Rep       Date:  2011-12

3.  Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).

Authors:  Yiyi Zhang; Robert Kennedy; Elena Blasco-Colmenares; Barbara Butcher; Sanaz Norgard; Zayd Eldadah; Timm Dickfeld; Kenneth A Ellenbogen; Joseph E Marine; Eliseo Guallar; Gordon F Tomaselli; Alan Cheng
Journal:  Heart Rhythm       Date:  2014-05-02       Impact factor: 6.343

4.  An analysis of patient-sharing physician networks and implantable cardioverter defibrillator therapy.

Authors:  Erika L Moen; Andrea M Austin; Julie P Bynum; Jonathan S Skinner; A James O'Malley
Journal:  Health Serv Outcomes Res Methodol       Date:  2016-06-27

Review 5.  Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies.

Authors:  Melissa H Kong; Eric D Peterson; Gregg C Fonarow; Gillian D Sanders; Clyde W Yancy; Andrea M Russo; Anne B Curtis; Samuel F Sears; Kevin L Thomas; Susan Campbell; Mark D Carlson; Chris Chiames; Nakela L Cook; David L Hayes; Michelle LaRue; Adrian F Hernandez; Edward L Lyons; Sana M Al-Khatib
Journal:  Am Heart J       Date:  2010-10       Impact factor: 4.749

6.  Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator: Insights From the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.

Authors:  Lucas N Marzec; Pamela N Peterson; Haikun Bao; Jeptha P Curtis; Frederick A Masoudi; Paul D Varosy; Steven M Bradley
Journal:  JAMA Cardiol       Date:  2017-05-01       Impact factor: 14.676

7.  Survival in Women Versus Men Following Implantation of Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy Devices in a Large, Nationwide Cohort.

Authors:  Niraj Varma; Suneet Mittal; Julie B Prillinger; Jeff Snell; Nirav Dalal; Jonathan P Piccini
Journal:  J Am Heart Assoc       Date:  2017-05-10       Impact factor: 5.501

8.  How Well Do Results From Randomized Clinical Trials and/or Recommendations for Implantable Cardioverter-Defibrillator Programming Diffuse Into Clinical Practice?Translation Assessed in a National Cohort of Patients With Implantable Cardioverter-Defibrillators ( ALTITUDE ).

Authors:  Niraj Varma; Paul Jones; Nicholas Wold; Edmond Cronin; Kenneth Stein
Journal:  J Am Heart Assoc       Date:  2019-02-05       Impact factor: 5.501

9.  Temporal Trends of Cardiac Implantable Electronic Device Implantations: a Nationwide Population-based Study.

Authors:  Ji Hyun Lee; So Ryoung Lee; Eue Keun Choi; Jaehan Jeong; Hyung Deuk Park; So Jeong You; Sang Soo Lee; Seil Oh
Journal:  Korean Circ J       Date:  2019-04-09       Impact factor: 3.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.